Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Stopped early · Phase 1
Conditions studied: Neoplasms Malignant
In brief
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
Key facts
- Study ID
- NCT01121588
- Run by
- Pfizer
- People needed
- 44
- Starts
- 2011-03-22
- Expected to finish
- 2023-09-07
- Last updated by the study team
- 2025-01-23
Who can join
Age: 15 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- histologically or cytologically proven diagnosis of malignancy other than NSCLC
- positive for translocation or inversion event involving the ALK gene locus
- positive for ALK amplification events
- positive for ALK activating point mutations
You may not qualify if…
- mutations of amplifications involving the c-Met gene but not the ALK gene
- concurrent treatment on another therapeutic clinical trial
- prior therapy specifically directed against ALK
Where it is running
- Highlands Oncology Group — Fayetteville, Arkansas, United States
- Highlands Oncology Group — Rogers, Arkansas, United States
- Highland Oncology Group — Springdale, Arkansas, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- OHSU Center for Health and Healing 2 — Portland, Oregon, United States
- Oregon Health & Science University — Portland, Oregon, United States
- Oregon Health and Science University — Portland, Oregon, United States
- Greenville Health System, Institute for Translational Oncology Research — Greenville, South Carolina, United States
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences — Beijing, Chaoyang District, China
- SUN Yat-Sen University Cancer Center — Guangzhou, Guangdong, China
- Centro di Ricerca di Fase 1 ASST-Monza — Monza, Italy
- PO San Gerardo, ASST Monza-U.O Ematologia — Monza, Italy
- National Hospital Organization Nagoya Medical Center — Nagoya, Aichi-ken, Japan
- National Cancer Center Hospital — Chuo-ku, Tokyo, Japan
- National Hospital Organization Kyushu Cancer Center — Fukuoka, Japan
- GBOU VPO "First Saint-Petersburg State Medical University n.a.I.P Pavlov" Ministry of Health — Saint Petersburg, Russia
- Institute of Pedriatric Oncology, Hematology and Transplantation n.a R.M Gorbacheva — Saint Petersburg, Russia
- Seoul National University Hospital — Seoul, South Korea
- Samsung Medical Center — Seoul, South Korea
- National Taiwan University Hospital, Department of Internal Medicine — Taipei, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.